Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) Net Margin (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Net Margin for 3 consecutive years, with 174.23% as the latest value for Q1 2025.

  • Quarterly Net Margin changed N/A to 174.23% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 1316.88% through Dec 2025, changed N/A year-over-year, with the annual reading at 1316.88% for FY2025, N/A changed from the prior year.
  • Net Margin for Q1 2025 was 174.23% at Centessa Pharmaceuticals, down from 1433.35% in the prior quarter.
  • The five-year high for Net Margin was 3911.74% in Q2 2022, with the low at 174.23% in Q1 2025.
  • Average Net Margin over 3 years is 2029.82%, with a median of 1959.74% recorded in 2022.
  • Peak annual rise in Net Margin hit -52639bps in 2023, while the deepest fall reached -289598bps in 2023.
  • Over 3 years, Net Margin stood at 1959.74% in 2022, then fell by -27bps to 1433.35% in 2023, then tumbled by -112bps to 174.23% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 174.23%, 1433.35%, and 1520.98% for Q1 2025, Q4 2023, and Q3 2023 respectively.